Asia Pacific COPD & Asthma Device Market to reach $15,893.9 Million by 2022, growing at a CAGR of 6.5% during 2016-2022
According to a recently published report by KBV Research, the Asia Pacific COPD & Asthma Device Market attained a market size of $ 10,267.8 Million in 2015 and is expected to reach $ 15,893.9 Million by 2022 growing at a CAGR of 6.5 % CAGR during 2016 – 2022.
The Metered Dose Inhalers (MDIs) market dominated the Asia Pacific COPD & Asthma Inhaler Market in 2015 and would continue till 2022, growing at a CAGR of 5.4 % during the forecast period. The Soft Mist Inhalers (SMIs) market is expected to reach a market size of $4,339.9 Million by 2022. The Dry Powder Inhalers (DPIs) market would witness the high growth rate of 8.7 % during 2016-2022.
The China market is expected to continue its dominance thereby growing at a CAGR of 7.0 % during the forecast period. The Japan market is expected to reach a market size of $ 1,796.0 Million by 2022. The India market would witness the high growth rate of 8.5 % during 2016-2022.
The report highlights the adoption of COPD & Asthma Devices in Asia Pacific. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market. The countries included in the report are Germany, UK, France, Russia, Spain, Italy and Rest of Asia Pacific.
Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.